Long-term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion

Background and Aim Transjugular intrahepatic portosystemic shunt (TIPS) is indicated for the treatment of refractory ascites in cirrhosis. The long‐term outcome of TIPS for refractory ascites is unknown. The aim of this study is to describe the natural history of patients with refractory ascites pos...

Full description

Saved in:
Bibliographic Details
Published in:Journal of gastroenterology and hepatology 2015-02, Vol.30 (2), p.389-395
Main Authors: Tan, Hiang Keat, James, Paul Damien, Sniderman, Kenneth Wilfred, Wong, Florence
Format: Article
Language:English
Subjects:
Age Factors
Ascites - therapy
cirrhosis
Female
Humans
Liver Cirrhosis - therapy
Male
Middle Aged
Polytetrafluoroethylene
portal hypertension
Portasystemic Shunt, Transjugular Intrahepatic - methods
Portasystemic Shunt, Transjugular Intrahepatic - mortality
refractory ascites
Retrospective Studies
Stents
Survival Rate
Time
transjugular intrahepatic portosystemic shunt
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Aim Transjugular intrahepatic portosystemic shunt (TIPS) is indicated for the treatment of refractory ascites in cirrhosis. The long‐term outcome of TIPS for refractory ascites is unknown. The aim of this study is to describe the natural history of patients with refractory ascites post‐TIPS, and compare between polytetrafluoroethylene (PTFE)‐covered versus bare stents. Methods A retrospective chart review of patients who had TIPS for refractory ascites was conducted. Prospectively collected data include demographics, angiographic data, blood work, and urinary sodium excretion. Results There were 136 patients who received TIPS (bare = 104, covered = 32) for over 22 years. Patients with PTFE stents had lower international normalized ratio and model for end‐stage liver disease score. More patients with bare stents developed shunt dysfunction (74.0% vs 24.1%, P 
ISSN:0815-9319
1440-1746
DOI:10.1111/jgh.12725